

### LISTING OF CLAIMS

1. (Currently amended) A method comprising  
topically administering a composition to an eye of a mammal,  
said method being effective in delivering a therapeutically effective amount of a  
therapeutically active agent to a structure or combination of structures of the eye which  
include the vitreous humor and structures posterior to the vitreous;  
said composition comprising:
  - a. an effective amount of the therapeutically active agent, or a  
pharmaceutically acceptable salt or prodrug thereof, to provide a  
therapeutically effective amount of the therapeutically active agent to said  
structure or combination of structures of the eye, and
  - b. an effective amount of a cyclodextrin to provide said therapeutically  
effective amount of said therapeutically active agent to said structure or  
combination of structures of the eye.

~~comprising a cyclodextrin and a therapeutically active agent, or a pharmaceutically acceptable salt or a prodrug thereof, to the eye of a mammal in need thereof, wherein said method is effective in improving delivery of said therapeutically active agent to the back of the eye.~~
2. (Original) The method of claim 1 wherein said mammal is a human.
3. (Original) The method of claim 1 wherein said therapeutically active agent, or salt or prodrug thereof, is water-insoluble.
4. (Original) The method of claim 1 wherein said therapeutically active agent, or salt or prodrug thereof, is water-soluble.
5. (Original) The method of claim 1 wherein said therapeutically active agent is not administered to reduce intraocular pressure.
6. (Original) The method of claim 1 wherein said therapeutically active agent is not administered to treat allergic conjunctivitis.
7. (Original) The method of claim 1 wherein said therapeutically active agent is not administered to treat dry eye.
8. (Original) The method of claim 1 wherein said therapeutically active agent is not administered to treat a condition affecting the front of the eye.

9. (Original) The method of claim 1 comprising a  $\beta$ -cyclodextrin derivative.
10. (Original) The method of claim 1 comprising a  $\beta$ -cyclodextrin derivative and a water-soluble polymer.
11. (Original) The method of claim 1 comprising prednisolone acetate, hydroxypropyl- $\beta$ -cyclodextrin, and hydroxypropylmethylcellulose.
12. (Original) The method of claim 1 comprising a  $\gamma$ -cyclodextrin derivative.
13. (Original) The method of claim 5 comprising prednisolone acetate.
14. (Original) The method of claim 5 wherein said cyclodextrin derivative is hydroxypropyl- $\gamma$ -cyclodextrin.
15. (Original) The method of claim 5 which further comprises a cellulose derivative.
16. (Original) The method of claim 5 which further comprises hydroxypropylmethylcellulose having a concentration less than 1%.
17. (Original) The method of claim 5 comprising from 0.05% to 0.4% hydroxypropylmethylcellulose.
18. (Original) The method of claim 5 comprising about from 0.1% to 0.25% hydroxypropylmethylcellulose.
19. (Original) A pharmaceutical product comprising a solution comprising a therapeutically active agent, or a pharmaceutically active salt or a prodrug thereof, and a cyclodextrin, wherein said solution has an ophthalmically acceptable pH, a container suitable for dispensing drops of said solution to the eye of a mammal in need of treatment by said prodrug, and a package which indicates that said product is useful for treatment of a disease or condition affecting the back of the eye.
20. (Currently amended) A composition comprising an effective amount of a therapeutically active agent or a pharmaceutically acceptable salt or prodrug thereof, and an effective amount of a cyclodextrin; wherein the amount of the therapeutically active agent or salt or prodrug thereof and the amount of the cyclodextrin are effective to deliver a therapeutically effective amount of

said therapeutically active agent to a structure or combination of structures of the eye which include the vitreous humor and structures posterior to the vitreous;  
wherein the therapeutically effective amount of the therapeutically active agent is delivered by administering said composition topically, ~~wherein said therapeutically active agent is intended for treatment or prevention of a disease or condition affecting the back of the eye and wherein said composition is suitable for topical ophthalmic administration.~~

21. (Original) The composition of claim 19 wherein said therapeutically active agent is not intended to reduce intraocular pressure.
22. (Original) The method of claim 19 wherein said therapeutically active agent is not intended to treat a condition affecting the front of the eye.
23. (Original) The composition of claim 20 comprising from 0.1% to 2% prednisolone acetate and from 1% to 30% of the cyclodextrin.
24. (Original) The composition of claim 23 comprising a  $\beta$ -cyclodextrin derivative.
25. (Original) The composition of claim 23 comprising a  $\gamma$ -cyclodextrin derivative.